Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CTXR Citius Pharmaceuticals	$1.67 +7.1%	$1.10	$0.65 ▼ $26.25	$17.75M	1.23	783,148 shs	1.33 million shs
INNT Innovate Biopharmaceuticals		$0.97	$0.37 ▼ $1.67	$8K	-0.39	525,982 shs	1,375 shs
KZIA Novogen	$11.43 +5.8%	$5.80	$2.86 ▼ $40.75	$11.54M	2.64	377,340 shs	152,537 shs
PVCT Provectus Biopharmaceuticals	$0.07 -4.3%	$0.08	$0.04 ▼ $0.15	$30.76M	0.75	195,869 shs	163,772 shs

A Beginner's Guide to Investing in Cannabis

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CTXR Citius Pharmaceuticals	+7.05%	-20.85%	+90.94%	+67.00%	-90.90%
INNT Innovate Biopharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%
KZIA Novogen	+5.83%	+74.50%	+22.90%	+215.27%	-74.48%
PVCT Provectus Biopharmaceuticals	-4.31%	-2.40%	-0.68%	-25.69%	-37.35%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CTXR Citius Pharmaceuticals	3.0566 of 5 stars	3.3	4.0	0.0	0.0	3.0	0.8	1.3
INNT Innovate Biopharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
KZIA Novogen	2.9874 of 5 stars	2.8	5.0	0.0	0.0	2.6	0.0	0.0
PVCT Provectus Biopharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CTXR Citius Pharmaceuticals	2.50	Moderate Buy	$53.00	3,073.65% Upside
INNT Innovate Biopharmaceuticals	0.00	N/A	N/A	N/A
KZIA Novogen	3.50	Strong Buy	$14.00	22.48% Upside
PVCT Provectus Biopharmaceuticals	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest INNT, KZIA, PVCT, and CTXR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/10/2025	KZIA Novogen	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Buy ➝ Strong-Buy	$13.00
6/30/2025	CTXR Citius Pharmaceuticals	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$6.00
6/11/2025	KZIA Novogen	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$15.00
6/9/2025	CTXR Citius Pharmaceuticals	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00
5/23/2025	CTXR Citius Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold
5/23/2025	CTXR Citius Pharmaceuticals	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/15/2025	CTXR Citius Pharmaceuticals	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00 ➝ $9.00

(Data available from 7/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CTXR Citius Pharmaceuticals	N/A	N/A	N/A	N/A	$10.25 per share	N/A
INNT Innovate Biopharmaceuticals	N/A	N/A	N/A	N/A	($0.27) per share	N/A
KZIA Novogen	$1.51M	7.65	N/A	N/A	($9.87) per share	-1.16
PVCT Provectus Biopharmaceuticals	$620K	49.62	N/A	N/A	($0.01) per share	-7.32

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CTXR Citius Pharmaceuticals	-$39.14M	N/A	0.00	1.34	N/A	N/A	-58.63%	-37.67%	8/11/2025 (Estimated)
INNT Innovate Biopharmaceuticals	-$27.05M	N/A	N/A	N/A	N/A	N/A	N/A	-234.42%	N/A
KZIA Novogen	-$17.56M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
PVCT Provectus Biopharmaceuticals	-$4.76M	N/A	0.00	∞	N/A	-815.81%	N/A	-644.80%	8/11/2025 (Estimated)

Latest INNT, KZIA, PVCT, and CTXR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/11/2025	Q3 2025	CTXR Citius Pharmaceuticals	-$0.76	N/A	N/A	N/A	$1.92 million	N/A
5/14/2025	Q2 2025	CTXR Citius Pharmaceuticals	-$1.08	-$1.27	-$0.19	-$1.27	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CTXR Citius Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
INNT Innovate Biopharmaceuticals	N/A	N/A	N/A	N/A	N/A
KZIA Novogen	N/A	N/A	N/A	N/A	N/A
PVCT Provectus Biopharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CTXR Citius Pharmaceuticals	N/A	0.37	0.06
INNT Innovate Biopharmaceuticals	N/A	0.35	0.35
KZIA Novogen	N/A	0.21	N/A
PVCT Provectus Biopharmaceuticals	N/A	0.11	0.11

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CTXR Citius Pharmaceuticals	16.88%
INNT Innovate Biopharmaceuticals	5.88%
KZIA Novogen	30.89%
PVCT Provectus Biopharmaceuticals	0.05%

Insider Ownership

Company	Insider Ownership
CTXR Citius Pharmaceuticals	10.70%
INNT Innovate Biopharmaceuticals	7.90%
KZIA Novogen	1.00%
PVCT Provectus Biopharmaceuticals	12.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CTXR Citius Pharmaceuticals	20	10.63 million	9.50 million	Optionable
INNT Innovate Biopharmaceuticals	8	41.33 million	N/A	Not Optionable
KZIA Novogen	12	1.01 million	997,000	Optionable
PVCT Provectus Biopharmaceuticals	4	420.28 million	366.48 million	Not Optionable

INNT, KZIA, PVCT, and CTXR Headlines

Recent News About These Companies

Provectus Biopharmaceuticals Announces Publication of Moffitt Cancer Center Research on PV-10 for Head and Neck Cancer - Morningstar

June 27, 2025 | morningstar.comM

Provectus Biopharmaceuticals Announces Publication of Moffitt Cancer Center Research on PV-10 for Head and Neck Cancer

June 26, 2025 | globenewswire.com

Provectus Biopharmaceuticals Announces Investor Webinar for 2025 Annual Meeting of Stockholders

June 9, 2025 | globenewswire.com

Croatia's Provectus Capital Partners opens office in Romania

April 24, 2025 | seenews.comS

Provectus announces $3M seed financing round for VisiRose

January 14, 2025 | markets.businessinsider.com

Provectus Biopharmaceuticals Announces Seed Financing for VisiRose, Provectus’s Spinoff Company for Rose Bengal-Based Eye Drugs

January 14, 2025 | markets.businessinsider.com

Provectus Biopharmaceuticals Announces Seed Financing for VisiRose, Provectus's Spinoff Company for Rose Bengal-Based Eye Drugs

January 14, 2025 | globenewswire.com

Provectus launches VisiRose, Provectus’s Founded Entity for pharmaceutical-grade rose bengal sodium-based treatments in ophthalmology

December 13, 2024 | pharmabiz.comP

Provectus announces the launch of VisiRose

December 12, 2024 | markets.businessinsider.com

VisiRose Introduces Revolutionary Therapy for Severe Eye Infections

December 10, 2024 | miamiherald.comM

Provectus Pharmaceuticals Aligns Leadership with Equity Grants

December 6, 2024 | markets.businessinsider.com

Provectus Pharmaceuticals to Reveal Key 2024 Updates

November 15, 2024 | markets.businessinsider.com

Provectus Biopharmaceuticals, Inc. (PVCT) Q4 2024 Earnings Call Transcript

November 14, 2024 | seekingalpha.com

Provectus Biopharmaceuticals Announces Investor Webinar for Fourth Quarter 2024 Conference Call

October 24, 2024 | manilatimes.netM

Provectus Biopharmaceuticals Announces Fourth Quarter 2024 Conference Call

October 10, 2024 | globenewswire.com

Provectus Biopharmaceuticals Announces Poster Presentation of Rose Bengal Sodium for Treatment of Full-Thickness Cutaneous Wounds at SID 2024 Annual Meeting

May 21, 2024 | finance.yahoo.com

Provectus Biopharmaceuticals Announces Eight Presentations of Rose Bengal Photodynamic Antimicrobial Therapy at ARVO 2024 Annual Meeting

May 14, 2024 | finance.yahoo.com

Provectus Biopharmaceuticals Announces Publication of Preclinical Data of Oral Administration of Provectus Rose Bengal for Solid Tumor Cancers

April 18, 2024 | finance.yahoo.com

Provectus Biopharmaceuticals Announces Management Additions and Reiterates Commitment to Shareholder Value Creation

April 16, 2024 | finance.yahoo.com

Provectus Biopharmaceuticals Announces Exclusive Worldwide License Agreement with University of Miami for Photodynamic Antimicrobial Treatment of Different Eye Infections with Rose Bengal Sodium

March 27, 2024 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

INNT, KZIA, PVCT, and CTXR Company Descriptions

Citius Pharmaceuticals NASDAQ:CTXR

$1.67 +0.11 (+7.05%)

Closing price 07/14/2025 04:00 PM Eastern

Extended Trading

$1.70 +0.03 (+1.50%)

As of 07/14/2025 07:58 PM Eastern

Citius Pharmaceuticals, Inc., a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome. The company was founded in 2007 and is headquartered in Cranford, New Jersey.

Innovate Biopharmaceuticals NASDAQ:INNT

Innovate Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for autoimmune and inflammatory diseases. The company's lead product candidate is INN-202 that has completed Phase IIb clinical trial for the treatment of celiac disease. It also develops INN-108, which has completed Phase I clinical trial to treat mild-to-moderate ulcerative colitis; INN-217 for the treatment of non-alcoholic steatohepatitis and microbiome; and INN-289 to treat crohn's disease, as well as product for the treatment of alcoholic steatohepatitis (ASH). In addition, the company holds rights for INN-329, a formulation of secretin that is used to enhance visualization in magnetic resonance cholangiopancreatography procedures that is in Phase III clinical trial. The company has a research collaboration with Massachusetts General Hospital for the treatment of ASH. Innovate Biopharmaceuticals, Inc. is based in Raleigh, North Carolina.

Novogen NASDAQ:KZIA

$11.43 +0.63 (+5.83%)

Closing price 07/14/2025 04:00 PM Eastern

Extended Trading

$11.34 -0.09 (-0.80%)

As of 07/14/2025 07:59 PM Eastern

Kazia Therapeutics Limited operates as an oncology-focused biotechnology company. The company's lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/AKT/mTOR pathway, which is developed as a potential therapy for glioblastoma. It also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.

Provectus Biopharmaceuticals OTCMKTS:PVCT

$0.07 0.00 (-4.31%)

As of 07/14/2025 03:54 PM Eastern

Provectus Biopharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing immunotherapy medicines based on halogenated xanthenes in the United States. The company's lead molecule is rose bengal sodium (RBS). Its clinical development programs include PV-10 for the treatment of stage III and IV melanoma and different types of liver cancers; PH-10 for the treatment of psoriasis and atopic dermatitis, and skin inflammation; and PV-305 for the treatment of infectious keratitis. It is also developing oral formulations for adult solid tumor cancers, as well as refractory and relapsed pediatric, and other blood cancers comprising leukemias; PV-10 for the treatment of relapsed and refractory pediatric solid tumor cancers; and other formulations for the treatment of cutaneous canine cancers and healing of full-thickness cutaneous wounds. In addition, the company develops oral and intranasal formulations for the treatment of severe acute respiratory syndrome coronavirus 2; gram-positive and gram-negative bacterial infections; oral bacterial infections; and fungal infections, as well as vertebrate development, wound healing, and tissue regrowth. It has collaboration agreement with Bascom Palmer Eye Institute; and University of Miami. The company was formerly known as Provectus Pharmaceuticals, Inc. and changed its name to Provectus Biopharmaceuticals, Inc. in December 2013. Provectus Biopharmaceuticals, Inc. was founded in 2002 and is based in Knoxville, Tennessee.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time